P-glycoprotein and Amyloid in M. Alzheimer

P-glycoprotein and Amyloid in M. Alzheimer - PIB PgP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31892

Enrollment

Registered

2008-12-10

Start date

2008-07-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease dementia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Meet the NINCDS-ADRDA criteria for probable Alzheimer's disease - Mild form of dementia (MMSE 19-22) - Older than 50 years Healthy controls do not meet NINCDS-ADRDA or MCI criteria.

Exclusion criteria

Exclusion criteria: - Use of medication that could influence Pgp function, e.g. digoxin, cyclosporin, amiodarone, steroïds, quinidin, colchicin, etoposide, antiestrogensn and atorvastatin. - Vasculair braindisease or otherwise braindiseases which could influence cerebral metabolism or perfusion. - Significant kidney or liverdisase. - Neurological symptoms not in agreement with a diagnosis of Alzheimer's disease. - Pregnancy. - Prior (excessive) radiation exposure in the same year (including radiological assistants or nuclear medicine employees).

Design outcomes

Primary

Measure	Time frame
Primary study parameters are the Pgp function, Aβ accumalation and their correlation in Alzheimer's disease and healty controls.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results